Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Ergebnis 12 von 32

Details

Autor(en) / Beteiligte
Titel
A Randomized, Controlled Trial of Magnesium Sulfate for the Prevention of Cerebral Palsy
Ist Teil von
  • The New England journal of medicine, 2008-08, Vol.359 (9), p.895-905
Ort / Verlag
Boston, MA: Massachusetts Medical Society
Erscheinungsjahr
2008
Quelle
MEDLINE
Beschreibungen/Notizen
  • In this multicenter, placebo-controlled, randomized trial of intravenous magnesium sulfate in women at imminent risk for delivery between 24 and 31 weeks of gestation, magnesium sulfate did not significantly reduce the primary composite outcome of moderate or severe cerebral palsy or death. However, it did result in a reduced rate of cerebral palsy among survivors (a prespecified secondary outcome), which may suggest the possibility of benefit. In women at imminent risk for delivery between 24 and 31 weeks of gestation, magnesium sulfate did not significantly reduce the primary composite outcome of moderate or severe cerebral palsy or death. However, it did result in a reduced rate of cerebral palsy among survivors. Cerebral palsy is characterized by abnormal control of movement and posture that results in limitation of activity. It is caused by nonprogressive damage or dysfunction of the developing fetal or infant brain 1 and is a leading cause of chronic childhood disability, with profound medical, emotional, and economic consequences. 2 Preterm birth is a risk factor for cerebral palsy, and the magnitude of the risk is inversely correlated with gestational age at birth. 3 During the past 20 to 30 years, the survival of infants born markedly preterm has improved dramatically, and whereas some data suggest that the rate of cerebral palsy among . . .

Weiterführende Literatur

Empfehlungen zum selben Thema automatisch vorgeschlagen von bX